Brazilian technology on the cutting edge of Endovascular Disease Treatments

In consonance with current trends in endovascular devices technology, as can be seen by the big companies’ moves, Biokyra is working on two products that may enhance the performance and ease the treatment of aortic aneurysms. The Endovascular Suture is a system capable of performing sutures by minimally invasive technique. An innovative tool to the surgeon, opening new possibilities to endovascular surgery and possibly also to other surgery specialities. This is a worldwide innovative product that represents an evolution in minimally invasive procedures. Click here to watch the video.

The company is also developing the Thoracoabdominal Aneurysm Treatment Stent Graft System: designed to provide an off-the-shelf solution for the treatment of thoracoabdominal aneurysms (TAAA), while used in combination with other standard commercially available devices. This hub endoprosthesis avoids the need for custom designed devices for the treatment of branched portions of the aorta and make the treatment available to more patients. You can watch the video here.

Biokyra is always looking for business opportunities and funding. If you have an idea for a medical device or if you are an investor who is interested in getting involved, contact us.

Medtronic investing in the Endovascular Business

It seems like Medtronic is interested to continue investing in aortic and peripheral vascular business, since it has been among its fastest-growing divisions for the past five years. The company has already disclosed an investment in Arsenal AAA, a subsidiary of Arsenal Medical - which develops technology to avoid complications linked to endovascular aneurysm repair (EVAR) procedures.

A few days after the announcement of this investment, Medtronic revealed its acquisition of Aptus Endosystems – maker of two FDA-cleared fastening devices and a steerable catheter for delivery of peripheral vascular products, which Medtronic will distribute. This statement was made during the Society for Vascular Surgery’s annual meeting.

    In a press release, the company said that these two investments were “demonstrations of Medtronic’s’ commitment to leadership in the Aortic space.” According to ReportsnReports.com, the market for aortic stent grafts is expected to increase at a compound annual growth rate of 6.7% until 2020, when it is expected to reach $1.9 billion. The market research company still states  “Despite the high product price, physicians still see a significant benefit in providing endovascular options ahead of performing open surgery”.

References:

http://www.mddionline.com/article/medtronic-moves-advance-aortic-business-06-19-15